Weiyu Zhao1, Chengxiang Zhang1, Bin Li1, Xinfu Zhang1, Xiao Luo1, Chunxi Zeng1, Wenqing Li1, Min Gao2, Yizhou Dong1,3,4,5,6,7. 1. Division of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, 434 Riffe Building, 496 West 12th Avenue, Columbus, OH 43210 USA. 2. Liquid Crystal Institute, Kent State University, Kent, OH 44242 USA. 3. Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210 USA. 4. The Center for Clinical and Translational Science, The Ohio State University, Columbus, OH 43210 USA. 5. The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210 USA. 6. Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210 USA. 7. Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210 USA.
Abstract
INTRODUCTION: In the past decade, messenger RNA (mRNA) has been extensively explored in a wide variety of biomedical applications. However, efficient delivery of mRNA is still one of the key challenges for its broad applications in the clinic. Recently, lipid polymer hybrid nanoparticles (LPNs) are evolving as a promising class of biomaterials for RNA delivery, which integrate the physicochemical properties of both lipids and polymers. We previously developed an N1,N3,N5-tris(2-aminoethyl)benzene-1,3,5-tricarboxamide (TT) derived lipid-like nanomaterial (TT3-LLN) which was capable of effectively delivering multiple types of mRNA. In order to further improve the delivery efficiency of TT3-LLN, in this study, we focused on studying the effects of incorporating different polymers on establishing LPNs and aimed to develop an optimized lipid polymer hybrid nanomaterial for efficient mRNA delivery. METHODS: We incorporated a series of biodegradable and biocompatible polymer materials into the formulation of TT3-LLNs to develop LPNs. mRNA delivery efficiency of different LPNs were evaluated and a systematic orthogonal optimization was further carried out. RESULTS: Our data indicate that PLGA4 (MW 24,000-38,000 g/mol) dramatically increased delivery efficiency of TT3-LLNs in comparison to other polymers. Further optimization identified PLGA4-7 LPNs (PLGA:mRNA=9:1, mass ratio; TT3:DOPE:Cholesterol:DMG-PEG2000=25:25:45:0.75, molar ratio) as a lead formulation, which displayed significantly enhanced delivery of two types of mRNA in three different human cell lines as compared with TT3-LLNs. CONCLUSIONS: Results from this study potentially provide new insights into developing LPNs for mRNA based therapeutics.
INTRODUCTION: In the past decade, messenger RNA (mRNA) has been extensively explored in a wide variety of biomedical applications. However, efficient delivery of mRNA is still one of the key challenges for its broad applications in the clinic. Recently, lipid polymer hybrid nanoparticles (LPNs) are evolving as a promising class of biomaterials for RNA delivery, which integrate the physicochemical properties of both lipids and polymers. We previously developed an N1,N3,N5-tris(2-aminoethyl)benzene-1,3,5-tricarboxamide (TT) derived lipid-like nanomaterial (TT3-LLN) which was capable of effectively delivering multiple types of mRNA. In order to further improve the delivery efficiency of TT3-LLN, in this study, we focused on studying the effects of incorporating different polymers on establishing LPNs and aimed to develop an optimized lipid polymer hybrid nanomaterial for efficient mRNA delivery. METHODS: We incorporated a series of biodegradable and biocompatible polymer materials into the formulation of TT3-LLNs to develop LPNs. mRNA delivery efficiency of different LPNs were evaluated and a systematic orthogonal optimization was further carried out. RESULTS: Our data indicate that PLGA4 (MW 24,000-38,000 g/mol) dramatically increased delivery efficiency of TT3-LLNs in comparison to other polymers. Further optimization identified PLGA4-7 LPNs (PLGA:mRNA=9:1, mass ratio; TT3:DOPE:Cholesterol:DMG-PEG2000=25:25:45:0.75, molar ratio) as a lead formulation, which displayed significantly enhanced delivery of two types of mRNA in three different human cell lines as compared with TT3-LLNs. CONCLUSIONS: Results from this study potentially provide new insights into developing LPNs for mRNA based therapeutics.
Authors: Yizhou Dong; J Robert Dorkin; Weiheng Wang; Philip H Chang; Matthew J Webber; Benjamin C Tang; Junghoon Yang; Inbal Abutbul-Ionita; Dganit Danino; Frank DeRosa; Michael Heartlein; Robert Langer; Daniel G Anderson Journal: Nano Lett Date: 2016-01-13 Impact factor: 11.189
Authors: James C Kaczmarek; Asha K Patel; Kevin J Kauffman; Owen S Fenton; Matthew J Webber; Michael W Heartlein; Frank DeRosa; Daniel G Anderson Journal: Angew Chem Int Ed Engl Date: 2016-09-30 Impact factor: 15.336
Authors: Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi Journal: Biomater Sci Date: 2015-08-17 Impact factor: 6.843
Authors: Lena M Kranz; Mustafa Diken; Heinrich Haas; Sebastian Kreiter; Carmen Loquai; Kerstin C Reuter; Martin Meng; Daniel Fritz; Fulvia Vascotto; Hossam Hefesha; Christian Grunwitz; Mathias Vormehr; Yves Hüsemann; Abderraouf Selmi; Andreas N Kuhn; Janina Buck; Evelyna Derhovanessian; Richard Rae; Sebastian Attig; Jan Diekmann; Robert A Jabulowsky; Sandra Heesch; Jessica Hassel; Peter Langguth; Stephan Grabbe; Christoph Huber; Özlem Türeci; Ugur Sahin Journal: Nature Date: 2016-06-01 Impact factor: 49.962